Klin Farmakol Farm. 2023;37(3):102-107 | DOI: 10.36290/far.2023.018

Population approach in pharmacokinetic analysis

Jan Hlaváč, Martin Šíma, Ondřej Slanař
Farmakologický ústav, 1. lékařská fakulta Univerzita Karlova a Všeobecná fakultní nemocnice v Praze

Population pharmacokinetics is a field of pharmacology that aims to create a mathematical model describing the pharmacokinetics of a drug in a population, including its variability. This article provides an insight into this field and explains the terminology to better understand the studies. The method is introduced in the context of pharmacology as a whole, with an emphasis on pharmacokinetics and the use of statistical models for optimal dosing. The next section is a quick summary of the history of pharmacokinetics after the creation of NONMEM with a follow-up on computerized data processing today. The following section focuses on model building, various approaches to parameter estimation including the Bayesian method, and continues with validation methods, followed by a short section on parameter covariance. Finally, the benefits and positives of population pharmacokinetics are summarized and a discussion of its limitations and perspectives is provided.

Keywords: population pharmacokinetics, non-linear mixed-effects modeling, Bayesian statistics, pharmacokinetic model.

Accepted: October 12, 2023; Published: October 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlaváč J, Šíma M, Slanař O. Population approach in pharmacokinetic analysis. Klin Farmakol Farm. 2023;37(3):102-107. doi: 10.36290/far.2023.018.
Download citation

References

  1. Committee for Medicinal Products for Human Use (CHMP). Guideline on reporting results from population pharmacokinetic analyses. Doc. Ref. CHMP/EWP/185990/06z. [Internet] 2007. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf.
  2. Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12(3):537-562. Go to original source... Go to PubMed...
  3. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6):553-571. Go to original source... Go to PubMed...
  4. Owen JS, Fiedler-Kelly J. Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models. CPT Pharmacometrics Syst Pharmacol. 2014;3(12):e153. Go to original source... Go to PubMed...
  5. Alsultan A, Alghamdi WA, Alghamdi J, et al. Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. Saudi Pharm J. 2020;28(10):1217-1227. Go to original source... Go to PubMed...
  6. Chaturvedula A. Population Pharmacokinetics. In: Jann MW, Penzak SR, Cohen LJ, editors. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. eBook: Adis Cham; 2016;71-90. Go to original source...
  7. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer; 2011. Go to original source...
  8. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-569. Go to original source... Go to PubMed...
  9. Carter AA, Rosenbaum SE, Dudley MN. Review of Methods in Population Pharmacokinetics. Clinical Research and Regulatory Affairs. 1995;12(1):21. Go to original source...
  10. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187-2197. Go to original source... Go to PubMed...
  11. Nomura K, Morikawa N, Ikawa K, et al. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother. 2008;61(4):892-900. Go to original source... Go to PubMed...
  12. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-151. Go to original source... Go to PubMed...
  13. Zhu M, Doshi S, Gisleskog PO, et al. Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. J Pharm Sci. 2014;103(1):328-336. Go to original source... Go to PubMed...
  14. Kirsch S. Covariance and Correlation. Mathematics for Machine Learning, Probability and Statistics [Internet] 2021. Available from: https://programmathically.com/covariance-and-correlation/.
  15. Yanagisawa H, Kawamata O, Ueda K. Modeling Emotions Associated With Novelty at Variable Uncertainty Levels: A Bayesian Approach. Front Comput Neurosci. 2019;13:2. Go to original source... Go to PubMed...
  16. Lu C, Zhang Y, Chen M, et al. Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. Antimicrob Agents Chemother. 2016;60(11):6619-6625. Go to original source... Go to PubMed...
  17. Shemesh CS, Chanu P, Jamsen K, et al. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer. 2019;7(1):314. Go to original source... Go to PubMed...
  18. Ni SQ, Zhao W, Wang J, et al. Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. Acta Pharmacol Sin. 2013;34(7):969-975. Go to original source... Go to PubMed...
  19. Jeong SH, Jang JH, Cho HY, et al. Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects. Pharmaceutics. 2020;12(4):374. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.